Table 1 Clinical characteristics of the studied cohorts.
Variable | NYP-WCMC cohort | NYP-LMH validation cohort | ||||||
|---|---|---|---|---|---|---|---|---|
All | Mild stratum | Intermediate stratum | Severe stratum | All | Mild stratum | Intermediate stratum | Severe stratum | |
# of patients (%) | 318 | 76 (23.90) | 116 (36.48) | 126 (39.62) | 84 | 10 (11.90) | 35 (41.67) | 39 (46.43) |
Demographics | ||||||||
Age, mean (SD) | 62.78 (14.34) | 61.47 (16.51) | 60.53 (14.14) | 65.64 (12.52) | 66.06 (13.06) | 61.00 (17.10) | 61.63 (11.46) | 71.33 (11.07) |
Sex female, n (%) | 100 (31.45%) | 23 (30.26%) | 38 (32.76%) | 39 (30.95%) | 33 (39.29%) | 4 (40.00%) | 19 (54.29%) | 10 (25.64%) |
Caucasian, n (%) | 91 (28.62%) | 20 (26.32%) | 39 (33.62%) | 32 (25.40%) | 7 (8.33%) | 0 (0.00%) | 4 (11.43%) | 3 (7.69%) |
African American, n (%) | 27 (8.49%) | 3 (3.95%) | 5 (4.31%) | 19 (15.08%) | 7 (8.33%) | 0 (0.00%) | 0 (0.00%) | 7 (17.95%) |
Asian/Pacific Islander, n (%) | 33 (10.38%) | 11 (14.47%) | 9 (7.76%) | 13 (10.32%) | 32 (38.10%) | 5 (50.00%) | 12 (34.29%) | 15 (38.46%) |
Multi-racial, n (%) | 86 (27.04%) | 21 (27.63%) | 34 (29.31%) | 31 (24.60%) | 10 (11.90%) | 2 (20.00%) | 5 (14.29%) | 3 (7.69%) |
BMI, mean (SD) | 29.53 (8.40) | 29.23 (9.06) | 30.75 (9.17) | 28.59 (7.01) | 28.70 (7.70) | 26.67 (3.94) | 30.03 (9.94) | 28.03 (5.61) |
Comorbidities | ||||||||
Coronary artery disease, n (%) | 49 (15.41%) | 7 (9.21%) | 17 (14.66%) | 25 (19.84%) | 11 (13.10%) | 1 (10.00%) | 1 (2.86%) | 9 (23.08%) |
Cerebrovascular accident (stroke), n (%) | 20 (6.29%) | 3 (3.95%) | 7 (6.03%) | 10 (7.94%) | 4 (4.76%) | 0 (0.00%) | 0 (0.00%) | 4 (10.26%) |
Heart failure, n (%) | 21 (6.60%) | 3 (3.95%) | 9 (7.76%) | 9 (7.14%) | 3 (3.57%) | 0 (0.00%) | 1 (2.86%) | 2 (5.13%) |
Hypertension, n (%) | 167 (52.52%) | 35 (46.05%) | 57 (49.14%) | 75 (59.52%) | 50 (59.52%) | 5 (50.00%) | 17 (48.57%) | 28 (71.79%) |
Diabetes mellitus, n (%) | 94 (29.56%) | 17 (22.37%) | 30 (25.86%) | 47 (37.30%) | 35 (41.67%) | 4 (40.00%) | 12 (34.29%) | 19 (48.72%) |
Pulmonary disease, n (%) | 63 (19.81%) | 15 (19.74%) | 22 (18.97%) | 26 (20.63%) | 15 (17.86%) | 2 (20.00%) | 4 (11.43%) | 9 (23.08%) |
Renal disease, n (%) | 26 (8.18%) | 5 (6.58%) | 5 (4.31%) | 16 (12.70%) | 7 (8.33%) | 0 (0.00%) | 2 (5.71%) | 5 (12.82%) |
Cirrhosis, n (%) | 5 (1.57%) | 3 (3.95%) | 0 (0.00%) | 2 (1.59%) | 1 (1.19%) | 0 (0.00%) | 0 (0.00%) | 1 (2.56%) |
Hepatitis, n (%) | 4 (1.26%) | 1 (1.32%) | 0 (0.00%) | 3 (2.38%) | 2 (2.38%) | 0 (0.00%) | 1 (2.86%) | 1 (2.56%) |
HIV, n (%) | 4 (1.26%) | 1 (1.32%) | 2 (1.72%) | 1 (0.79%) | 1 (1.19%) | 0 (0.00%) | 1 (2.86%) | 0 (0.00%) |
Active cancer, n (%) | 21 (6.60%) | 3 (3.95%) | 2 (1.72%) | 16 (12.70%) | 2 (2.38%) | 0 (0.00%) | 0 (0.00%) | 2 (5.13%) |
Transplant, n (%) | 14 (4.40%) | 5 (6.58%) | 3 (2.59%) | 6 (4.76%) | 1 (1.19%) | 0 (0.00%) | 0 (0.00%) | 1 (2.56%) |
Inflammatory bowel disease, n (%) | 7 (2.20%) | 2 (2.63%) | 2 (1.72%) | 3 (2.38%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
Rheumatologic disease, n (%) | 15 (4.72%) | 4 (5.26%) | 3 (2.59%) | 8 (6.35%) | 3 (3.57%) | 0 (0.00%) | 2 (5.71%) | 1 (2.56%) |
Other immunosuppressed state, n (%) | 12 (3.77%) | 4 (5.26%) | 1 (0.86%) | 7 (5.56%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
Baseline SOFA scores | ||||||||
Cardiovascular, mean (SD) | 3.02 (1.35) | 1.32 (1.34) | 3.41 (0.88) | 3.69 (0.70) | 3.45 (1.03) | 1.40 (1.02) | 3.57 (0.80) | 3.87 (0.40) |
Central nervous system, mean (SD) | 3.72 (0.68) | 3.34 (1.13) | 3.72 (0.47) | 3.94 (0.24) | 3.39 (0.74) | 2.60 (1.36) | 3.37 (0.48) | 3.62 (0.54) |
Coagulation, mean (SD) | 0.15 (0.47) | 0.12 (0.40) | 0.04 (0.20) | 0.28 (0.64) | 0.13 (0.40) | 0.00 (0.00) | 0.11 (0.40) | 0.18 (0.45) |
Liver, mean (SD) | 0.24 (0.56) | 0.20 (0.46) | 0.14 (0.43) | 0.37 (0.67) | 0.20 (0.48) | 0.10 (0.30) | 0.14 (0.42) | 0.28 (0.55) |
Renal, mean (SD) | 0.94 (1.32) | 0.16 (0.54) | 0.35 (0.67) | 1.96 (1.44) | 1.36 (1.35) | 0.50 (0.67) | 0.37 (0.64) | 2.46 (1.08) |
Respiration, mean (SD) | 3.81 (0.58) | 3.45 (0.89) | 3.89 (0.45) | 3.97 (0.25) | 3.98 (0.22) | 4.00 (0.00) | 3.94 (0.33) | 4.00 (0.00) |
SOFA score, mean (SD) | 11.89 (2.56) | 8.58 (1.84) | 11.55 (0.58) | 14.20 (1.46) | 12.51 (2.25) | 8.60 (2.11) | 11.51 (0.50) | 14.41 (1.08) |
30-Day clinical outcomes | ||||||||
Extubation, n (%) | 138 (43.40%) | 40 (52.63%) | 54 (46.55%) | 44 (34.92%) | 31 (36.90%) | 2 (20.00%) | 15 (42.86%) | 14 (35.90%) |
Mortality, n (%) | 77 (24.21%) | 14 (18.42%) | 18 (15.52%) | 45 (35.71%) | 26 (30.95%) | 4 (40.00%) | 8 (22.86%) | 14 (35.90%) |
Tracheostomy, n (%) | 41 (12.89%) | 10 (13.16%) | 18 (15.52%) | 13 (10.32%) | 6 (7.14%) | 0 (0.00%) | 3 (8.57%) | 3 (7.69%) |
